<DOC>
	<DOCNO>NCT01944839</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy intravitreal administration Fovista® administer combination Lucentis® compare Lucentis® monotherapy subject subfoveal choroidal neovascularization secondary age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>A Phase 3 Safety Efficacy Study Fovista® ( E10030 ) Intravitreous Administration Combination With Lucentis® Compared Lucentis® Monotherapy</brief_title>
	<detailed_description>Subjects randomize 1:1 ratio follow dose group : - Fovista® 1.5 mg/eye + Lucentis® 0.5 mg/eye - Fovista® sham + Lucentis® 0.5 mg/eye Subjects treat total 24 month active Fovista® sham combination Lucentis® primary endpoint 12 month . Primary Efficacy Endpoint : The primary efficacy endpoint mean change visual acuity ( ETDRS letter ) baseline month 12 visit . Safety Endpoints : Safety endpoint include adverse event , vital sign , ophthalmic variable [ ophthalmic examination , intraocular pressure ( IOP ) , fluorescein angiogram ( FA ) , optical coherence tomography ( OCT ) ] , ECG , laboratory variable . Approximately 622 subject randomize one two treatment cohort ( 311 patient per dose group ) .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Subjects either gender age ≥ 50 year Active subfoveal choroidal neovascularization ( CNV ) secondary AMD Presence subretinal hyperreflective material ( SDOCT ) Any prior treatment AMD study eye prior Day 1 visit , except oral supplement vitamin mineral Any prior intravitreal treatment study eye prior Day 1 visit , regardless indication ( include intravitreal corticosteroid ) Any intraocular surgery thermal laser within three ( 3 ) month trial entry . Any prior thermal laser macular region , regardless indication Subjects subfoveal scar subfoveal atrophy exclude Diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Wet AMD</keyword>
	<keyword>choroidal neovascularization</keyword>
	<keyword>Fovista®</keyword>
	<keyword>E10030</keyword>
	<keyword>Lucentis®</keyword>
</DOC>